Biogen Inc. Files 2023 Annual Report on Form 10-K

Ticker: BIIB · Form: 10-K · Filed: 2024-02-14T00:00:00.000Z

Sentiment: neutral

Topics: Biogen, 10-K, Annual Report, Biotechnology, Financials

TL;DR

<b>Biogen Inc. has submitted its 2023 annual report on Form 10-K, detailing its financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

BIOGEN INC. (BIIB) filed a Annual Report (10-K) with the SEC on February 14, 2024. Biogen Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The report covers the period from January 1, 2023, to December 31, 2023. The company's principal executive offices are located at 225 Binney Street, Cambridge, MA 02142. Biogen Inc. was previously known as Biogen Idec Inc. and Idec Pharmaceuticals Corp. The filing includes financial data for the years 2023, 2022, and 2021.

Why It Matters

For investors and stakeholders tracking BIOGEN INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Biogen's financial health, operational results, and strategic positioning for the past fiscal year, which is crucial for investors to assess the company's performance and future prospects. The detailed financial statements and risk factors disclosed in this report are essential for stakeholders to understand the company's revenue streams, profitability, debt levels, and potential challenges in the biotechnology sector.

Risk Assessment

Risk Level: medium — BIOGEN INC. shows moderate risk based on this filing. The company operates in the highly regulated biotechnology sector, facing risks related to drug development, clinical trials, regulatory approvals, and market competition, as evidenced by the numerous risk factors typically detailed in a 10-K filing.

Analyst Insight

Investors should review the detailed financial statements and management's discussion and analysis in the 10-K to understand Biogen's revenue drivers, R&D investments, and competitive landscape.

Key Numbers

Key Players & Entities

FAQ

When did BIOGEN INC. file this 10-K?

BIOGEN INC. filed this Annual Report (10-K) with the SEC on February 14, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by BIOGEN INC. (BIIB).

Where can I read the original 10-K filing from BIOGEN INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by BIOGEN INC..

What are the key takeaways from BIOGEN INC.'s 10-K?

BIOGEN INC. filed this 10-K on February 14, 2024. Key takeaways: Biogen Inc. filed its 10-K report for the fiscal year ending December 31, 2023.. The report covers the period from January 1, 2023, to December 31, 2023.. The company's principal executive offices are located at 225 Binney Street, Cambridge, MA 02142..

Is BIOGEN INC. a risky investment based on this filing?

Based on this 10-K, BIOGEN INC. presents a moderate-risk profile. The company operates in the highly regulated biotechnology sector, facing risks related to drug development, clinical trials, regulatory approvals, and market competition, as evidenced by the numerous risk factors typically detailed in a 10-K filing.

What should investors do after reading BIOGEN INC.'s 10-K?

Investors should review the detailed financial statements and management's discussion and analysis in the 10-K to understand Biogen's revenue drivers, R&D investments, and competitive landscape. The overall sentiment from this filing is neutral.

How does BIOGEN INC. compare to its industry peers?

Biogen operates within the biotechnology industry, focusing on the discovery, development, manufacturing, and commercialization of therapies for neurological and neurodegenerative diseases.

Are there regulatory concerns for BIOGEN INC.?

As a biotechnology company, Biogen is subject to extensive regulation by health authorities like the FDA for drug approval, manufacturing standards, and marketing practices.

Industry Context

Biogen operates within the biotechnology industry, focusing on the discovery, development, manufacturing, and commercialization of therapies for neurological and neurodegenerative diseases.

Regulatory Implications

As a biotechnology company, Biogen is subject to extensive regulation by health authorities like the FDA for drug approval, manufacturing standards, and marketing practices.

What Investors Should Do

  1. Analyze Biogen's revenue breakdown by therapeutic area and product for FY2023.
  2. Review the company's R&D expenses and pipeline updates disclosed in the 10-K.
  3. Assess the key risks and uncertainties outlined in the 'Risk Factors' section of the filing.

Year-Over-Year Comparison

This filing is the 2023 annual report, following previous filings which would include quarterly reports (10-Q) and potentially prior annual reports (10-K).

Filing Stats: 4,373 words · 17 min read · ~15 pages · Grade level 14.8 · Accepted 2024-02-13 17:40:44

Key Financial Figures

Filing Documents

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 40 Item 1B. Unresolved Staff Comments 54 Item 1C. Cybersecurity 54 Item 2.

Properties

Properties 55 Item 3.

Legal Proceedings

Legal Proceedings 57 Item 4. Mine Safety Disclosures 57 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 58 Item 6. Reserved 59 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 60 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 91 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 93 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 93 Item 9A.

Controls and Procedures

Controls and Procedures 93 Item 9B. Other Information 94 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 95 PART III Item 10. Directors, Executive Officers and Corporate Governance 96 Item 11.

Executive Compensation

Executive Compensation 96 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 96 Item 13. Certain Relationships and Related Transactions, and Director Independence 96 Item 14. Principal Accountant Fees and Services 96 PART IV Item 15. Exhibits and Financial Statement Schedules 97 Item 16. Form 10-K Summary 97

Signatures

Signatures 100 Consolidated Financial Statements F- 1 T able of Contents NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the "Safe Harbor" provisions of the Act. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "contemplate," "continue," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "potential," "possible," "predict," "project", "should," "target," "will," "would" or the negative of these words or other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding: the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; our plans and investments in our

BUSINESS

ITEM 1. BUSINESS OVERVIEW Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer's disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations. Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD and we have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche

View on Read The Filing